Biocardia Stock Buy Hold or Sell Recommendation
| BCDA Stock | USD 2.12 0.07 3.41% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Biocardia is 'Strong Sell'. Macroaxis provides Biocardia buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BCDA positions.
Check out Biocardia Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide. In addition, we conduct extensive research on individual companies such as Biocardia and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Biocardia |
Execute Biocardia Buy or Sell Advice
The Biocardia recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biocardia. Macroaxis does not own or have any residual interests in Biocardia or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biocardia's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Biocardia Trading Alerts and Improvement Suggestions
| Biocardia generated a negative expected return over the last 90 days | |
| Biocardia has high historical volatility and very poor performance | |
| Biocardia has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 477 K. Net Loss for the year was (11.57 M) with loss before overhead, payroll, taxes, and interest of (4.06 M). | |
| Biocardia currently holds about 8.61 M in cash with (9.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49. | |
| Roughly 21.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 |
Biocardia Returns Distribution Density
The distribution of Biocardia's historical returns is an attempt to chart the uncertainty of Biocardia's future price movements. The chart of the probability distribution of Biocardia daily returns describes the distribution of returns around its average expected value. We use Biocardia price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biocardia returns is essential to provide solid investment advice for Biocardia.
| Mean Return | 0.12 | Value At Risk | -6.93 | Potential Upside | 7.07 | Standard Deviation | 4.94 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biocardia historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biocardia Stock Institutional Investors
| Shares | Sbi Securities Co Ltd | 2024-12-31 | 15.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Susquehanna International Group, Llp | 2024-12-31 | 43.8 K | Geode Capital Management, Llc | 2024-12-31 | 31 K | Cm Management, Llc | 2024-12-31 | 25 K | Vanguard Group Inc | 2024-12-31 | 12.9 K | Ubs Group Ag | 2024-12-31 | 4.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4 K | Pingora Partners Llc | 2024-12-31 | 1 K | Tower Research Capital Llc | 2024-12-31 | 535 | Bank Of America Corp | 2024-12-31 | 413 |
Biocardia Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 15.8M | (8.5M) | (5.5M) | (6.3M) | (5.6M) | (5.4M) | |
| Free Cash Flow | (12.4M) | (10.5M) | (10.6M) | (10.0M) | (9.0M) | (8.5M) | |
| Depreciation | 68K | 60K | 82K | 84K | 75.6K | 149.0K | |
| Other Non Cash Items | 3K | 19K | 295K | 331K | 380.7K | 399.7K | |
| Capital Expenditures | 32K | 116K | 70K | 12K | 13.8K | 13.1K | |
| Net Income | (15.0M) | (12.6M) | (11.9M) | (11.6M) | (10.4M) | (9.9M) | |
| End Period Cash Flow | 21.4M | 12.9M | 7.4M | 1.1M | 1.3M | 1.2M | |
| Change To Inventory | 49K | 136K | 4K | 507K | 583.1K | 612.2K | |
| Change To Netincome | 2.8M | 3.3M | 2.4M | 1.7M | 1.9M | 2.1M | |
| Investments | (32K) | (116K) | (70K) | (12K) | (10.8K) | (10.3K) |
Biocardia Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biocardia or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biocardia's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biocardia stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.10 | |
β | Beta against Dow Jones | 1.29 | |
σ | Overall volatility | 5.03 | |
Ir | Information ratio | 0.02 |
Biocardia Volatility Alert
Biocardia exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biocardia's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biocardia's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biocardia Fundamentals Vs Peers
Comparing Biocardia's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biocardia's direct or indirect competition across all of the common fundamentals between Biocardia and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biocardia or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biocardia's fundamental indicators could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biocardia to competition |
| Fundamentals | Biocardia | Peer Average |
| Return On Equity | -7.38 | -0.31 |
| Return On Asset | -0.97 | -0.14 |
| Operating Margin | (109.35) % | (5.51) % |
| Current Valuation | 5.51 M | 16.62 B |
| Shares Outstanding | 4.58 M | 571.82 M |
| Shares Owned By Insiders | 20.87 % | 10.09 % |
| Shares Owned By Institutions | 2.72 % | 39.21 % |
| Number Of Shares Shorted | 53.72 K | 4.71 M |
| Price To Earning | (11.00) X | 28.72 X |
| Price To Book | 3.41 X | 9.51 X |
| Price To Sales | 132.36 X | 11.42 X |
| Revenue | 477 K | 9.43 B |
| Gross Profit | (4.06 M) | 27.38 B |
| EBITDA | (11.56 M) | 3.9 B |
| Net Income | (11.57 M) | 570.98 M |
| Cash And Equivalents | 8.61 M | 2.7 B |
| Cash Per Share | 0.49 X | 5.01 X |
| Total Debt | 1.31 M | 5.32 B |
| Debt To Equity | 0.26 % | 48.70 % |
| Current Ratio | 3.00 X | 2.16 X |
| Book Value Per Share | 0.61 X | 1.93 K |
| Cash Flow From Operations | (9.97 M) | 971.22 M |
| Short Ratio | 1.08 X | 4.00 X |
| Earnings Per Share | (4.03) X | 3.12 X |
| Target Price | 15.5 | |
| Number Of Employees | 16 | 18.84 K |
| Beta | 1.3 | -0.15 |
| Market Capitalization | 9.4 M | 19.03 B |
| Total Asset | 2.99 M | 29.47 B |
| Retained Earnings | (152.18 M) | 9.33 B |
| Working Capital | (2.15 M) | 1.48 B |
| Current Asset | 19.48 M | 9.34 B |
| Current Liabilities | 330 K | 7.9 B |
Note: Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 [view details]
Biocardia Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biocardia . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Biocardia Buy or Sell Advice
When is the right time to buy or sell Biocardia? Buying financial instruments such as Biocardia Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biocardia in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Thematic Idea Now
Construction
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biocardia Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.93) | Return On Assets | Return On Equity |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.